CLINICAL RESEARCH: CORONARY ARTERY DISEASE
Circulating Osteoprotegerin Levels and Long-Term Prognosis in Patients With Acute Coronary Syndromes
Torbjørn Omland, MD, PhD, MPH*, ,
Thor Ueland, PhD ,1,
Anna M. Jansson, MD ,
Anita Persson, MSc||,
Thomas Karlsson, MSc¶,
Camilla Smith, MD,
Johan Herlitz, MD, PhD¶,
Pål Aukrust, MD, PhD,1,
Marianne Hartford, MD, PhD¶,# and
Kenneth Caidahl, MD, PhD,||,*
* Department of Medicine, Akershus University Hospital, Lørenskog, Norway
Faculty of Medicine, University of Oslo, Oslo, Norway
Research Institute for Internal Medicine, Rikshospitalet, Oslo, Norway
Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
|| Department of Clinical Physiology, Sahlgrenska University Hospital, Göteborg, Sweden
¶ Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden
# AstraZeneca R&D, Mölndal, Sweden.
Manuscript received July 3, 2007;
revised manuscript received September 17, 2007,
accepted September 23, 2007.
* Reprint requests and correspondence: Dr. Kenneth Caidahl, Department of Clinical Physiology N2:01 & Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. (Email: kenneth.caidahl{at}ki.se).
Objectives: This study was designed to assess the association between osteoprotegerin (OPG) levels on admission and long-term prognosis in patients with acute coronary syndromes (ACS).
Background: Osteoprotegerin, a member of the tumor necrosis factor receptor superfamily, has pleiotropic effects on bone metabolism, endocrine function, and the immune system.
Methods: Serum samples for OPG analysis were obtained within 24 h of admission in 897 ACS patients (median age 66 years, 71% men) and related to the incidence of death, heart failure (HF) hospitalizations, myocardial infarction (MI), and stroke.
Results: A total of 261 patients died during a median follow-up of 89 months. The baseline OPG concentration was strongly associated with increased long-term mortality (hazard ratio [HR] for HR per 1 SD increase in logarithmically transformed OPG level 1.7 [range 1.5 to 1.9] p < 0.0001) and HF hospitalizations (HR 2.0 [range 1.6 to 2.5]; p < 0.0001) but weaker with recurrent MI (HR 1.3 [range 1.0 to 1.5]; p = 0.02) and not with stroke (HR 1.2 [range 0.9 to 1.6]; p = 0.35). After adjustment for conventional risk markers, including troponin I, C-reactive protein (CRP), B-type natriuretic peptide (BNP), and ejection fraction, the association remained significant for mortality (HR 1.4 [range 1.2 to 1.7]; p < 0.0001) and HF hospitalization (HR 1.6 [range 1.2 to 2.1]; p = 0.0002), but not recurrent MI. By comparison of the area under the receiver-operating characteristics curves, OPG performed similarly to BNP and ejection fraction and significantly better than CRP and troponin I as a predictor of death.
Conclusions: Serum OPG is strongly predictive of long-term mortality and HF development in patients with ACS, independent of conventional risk markers.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndromes | | BNP = B-type natriuretic peptide | | CI = confidence interval | | CRP = C-reactive protein | | HF = heart failure | | HR = hazard ratio | | LVEF = left ventricular ejection fraction | | MI = myocardial infarction | | OPG = osteoprotegerin | RANK = receptor activator of nuclear factor- B | | RANKL = receptor activator of nuclear factor-B ligand |
|
This article has been cited by other articles:
|
|
|
|
 
M. K. Sigrist, A. Levin, L. Er, and C. W. McIntyre
Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification
Nephrol. Dial. Transplant.,
October 1, 2009;
24(10):
3157 - 3162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hofso, T. Ueland, H. Hager, T. Jenssen, J. Bollerslev, K. Godang, P. Aukrust, J. Roislien, and J. Hjelmesaeth
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose
Eur. J. Endocrinol.,
September 1, 2009;
161(3):
451 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Semb, T. Ueland, P. Aukrust, N. J. Wareham, R. Luben, L. Gullestad, J. J.P. Kastelein, K.-T. Khaw, and S. M. Boekholdt
Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand and Risk for Coronary Events: A Nested Case-Control Approach in the Prospective EPIC-Norfolk Population Study 1993-2003
Arterioscler Thromb Vasc Biol,
June 1, 2009;
29(6):
975 - 980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nybo and L. M Rasmussen
The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review
Eur. J. Endocrinol.,
November 1, 2008;
159(5):
603 - 608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1095 - 1103.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. F Escobar-Morreale, J. I Botella-Carretero, M. A. Martinez-Garcia, M. Luque-Ramirez, F. Alvarez-Blasco, and J. L S. Millan
Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome
Eur. J. Endocrinol.,
September 1, 2008;
159(3):
225 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
